Concepedia

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

Robert B. Forbes, Andrew Lees, Norman Waugh, R. J. Swingler

BMJ · 1999 · 85 citations · 31 references

Open access

Abstract

The cost per QALY gained from interferon beta is high because of the high drug cost and modest clinical effect. Resources could be used more efficiently elsewhere.

References

31

EuroQol - a new facility for the measurement of health-related quality of life

Health Policy · 1990 · 15.5K citations

Quality Of Life, Life Assessment, Health Policy +7

New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

Charles M. Poser, Donald W. Paty, Labe C. Scheinberg et al. · Annals of Neurology · 1983 · 7.4K citations

Reliability, Neurological Disorder, Diagnostic Criterion +5

New Multiple Sclerosis Phenotypic Classification

Fred Lublin · European Neurology · 2014 · 4.2K citations

Defining the clinical course of multiple sclerosis

Fred Lublin, Stephen C. Reingold · Neurology · 1996 · 3.7K citations

Neurological Disorder, Patient Selection, Clinical Neurology +17

British National Formulary

Journal of the American Pharmaceutical Association (Scientific ed ) · 1958 · 2.5K citations

British National Formulary, Standardization, Specification (Technical Standard)